© 2004 European Society of Cardiology
NT-proBNP and BNP: biomarkers for heart failure management
Departamento de Medicina Interna, Serviço de Medicina B – Hospital S. João, Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto Porto, Portugal
* Serviço de Medicina B, Hospital S. João – Piso 4, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal. Tel.: +351-22-8327463; Fax: +351-22-5089788 E-mail address: pbettfer{at}esoterica.pt
 |
Abstract |
|---|
Guidelines for the pharmacological treatment of heart failure (HF) are based on results from large clinical trials demonstrating benefit. State of the art pharmacological management of HF assumes that target doses should be the same as those used in trials. Thus equal doses are recommended for all in practical guidelines, but this strategy might not fit individual needs. NT-proBNP and BNP emerged as potential biomarkers of clinical interest in HF management. NT-proBNP and BNP are related to HF severity and to clinical status. NT-proBNP and BNP are strongly associated with prognosis across the whole spectrum of HF patients. A pilot study has shown that NT-proBNP-guided therapy is associated with improved outcome in HF. Although at present there are still few data to make firm recommendations on the use of NT-proBNP or BNP levels as biomarkers for HF management, future studies will provide further insight on this issue.
Key Words: Heart failure • Natriuretic peptides • Prognosis • Mortality
Received November 21, 2003; Accepted January 15, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Frankenstein, C. Zugck, M. Nelles, D. Schellberg, H. A. Katus, and B. A. Remppis The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders Eur J Heart Fail, December 1, 2009; 11(12): 1189 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Bockeria, O. L. Bockeria, and U. A. Kolesnikova eComment: Re: Brain natriuretic peptide a predictive marker in cardiac surgery Interactive CardioVascular and Thoracic Surgery, October 1, 2009; 9(4): 666 - 666. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, Y. Zhou, L. Meng, X. Lu, N. Ou, and X. Li Inflammatory Mediators in Chinese Patients With Congestive Heart Failure J. Clin. Pharmacol., May 1, 2009; 49(5): 591 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Frankenstein, A. Remppis, M. Nelles, B. Schaelling, D. Schellberg, H. Katus, and C. Zugck Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status Eur. Heart J., November 1, 2008; 29(21): 2634 - 2640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jefic, J. W. Lee, D. Jefic, R. T. Savoy-Moore, and H. S. Rosman Utility of B-Type Natriuretic Peptide and N-terminal Pro B-Type Natriuretic Peptide in Evaluation of Respiratory Failure in Critically Ill Patients Chest, July 1, 2005; 128(1): 288 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Verdiani, C. Nozzoli, F. Bacci, A. Cecchin, M. S. Rutili, S. Paladini, and I. Olivotto Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit Eur J Heart Fail, June 1, 2005; 7(4): 566 - 571. [Abstract] [Full Text] [PDF]
|
|